Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Restructuring Costs (2023 - 2025)

Historic Restructuring Costs for Maravai Lifesciences Holdings (MRVI) over the last 3 years, with Q3 2025 value amounting to $7.4 million.

  • Maravai Lifesciences Holdings' Restructuring Costs rose 18475000.0% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 4090.74%. This contributed to the annual value of -$1.2 million for FY2024, which is 11877.51% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Restructuring Costs stood at $7.4 million, which was up 18475000.0% from $6000.0 recorded in Q4 2024.
  • In the past 5 years, Maravai Lifesciences Holdings' Restructuring Costs registered a high of $7.4 million during Q3 2025, and its lowest value of -$1.2 million during Q1 2024.
  • For the 3-year period, Maravai Lifesciences Holdings' Restructuring Costs averaged around $2.1 million, with its median value being $1000.0 (2024).
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Restructuring Costs tumbled by 9990.72% in 2024, and later surged by 18475000.0% in 2025.
  • Maravai Lifesciences Holdings' Restructuring Costs (Quarter) stood at $6.5 million in 2023, then crashed by 99.91% to $6000.0 in 2024, then skyrocketed by 123000.0% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $6000.0 for Q4 2024, and -$4000.0 during Q3 2024.